trial · primary record
The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332
Diffuse Large B-Cell Lymphoma (DLBCL)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 14 |
| Primary completion | 2029-06-30 |
| Primary endpoint | Feasibility of CIK (CIK_D332) cell therapy added to tafasitamab/lenalidomide in patients with relapsed/refractory DLBCL after at least one line of immuno-chemotherapy. |
| Registry ID | NCT07906080 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:36.796Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07906080
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.